Investigation of the Male Pattern Baldness Major Genetic Susceptibility Loci AR/EDA2R and 20p11 in Female Pattern Hair Loss

A 27-year-old woman with advanced female pattern hair loss and telogen effluvium is experiencing increased hair shedding after starting oral minoxidil and finasteride. She is seeking advice and reassurance from others who have experienced similar issues, while also considering additional treatments like dermapen and ensuring her nutritional needs are met.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

A user has been experiencing hair loss for 4 years, with treatments like minoxidil, finasteride, and various supplements proving ineffective. They were diagnosed with fibrosing alopecia in a pattern distribution, a condition that may require a combination of anti-inflammatory and hair growth treatments.

Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.

A 25-year-old male experienced significant hair loss due to telogen effluvium and androgenetic alopecia. He began using finasteride, minoxidil, and vitamins, seeing some regrowth but remains worried about hair density.

Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.